{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:17:56Z","timestamp":1773281876909,"version":"3.50.1"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:italic>Salmonella enterica<\/jats:italic>\n            serotype Typhi and nontyphoidal\n            <jats:italic>Salmonella<\/jats:italic>\n            remain major causes of morbidity and mortality worldwide. Ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol no longer provide reliable coverage of\n            <jats:italic>Salmonella<\/jats:italic>\n            , and fluoroquinoloes have emerged as first-line treatment options. Due to mounting evidence of decreased in vitro susceptibility and diminished clinical response to fluoroquinolone therapy, it has been suggested that the NCCLS breakpoints for the salmonellae be reevaluated. We utilized an in vitro infection model to determine which pharmacokinetic-pharmacodynamic (PK-PD) measure was most closely linked to fluoroquinolone activity against salmonellae and the magnitude that was predictive of efficacy. Monte Carlo simulation was utilized to determine the probability of attaining potential susceptibility breakpoints for three fluoroquinolones. The free-drug area under the concentration-time curve from 0 to 24 h\/MIC ratio was the PK-PD measure most predictive of efficacy, and a ratio of 105 corresponded to 90% of maximal activity. Simulation results suggested susceptible breakpoints of 0.12 \u03bcg\/ml for ciprofloxacin and gatifloxacin and 0.25 \u03bcg\/ml for levofloxacin. These proposed breakpoints correspond to the MIC separating the wild-type susceptible organism population from those strains possessing single-step mutations in the quinolone resistance-determining region. These results that integrate PK-PD measures and fluoroquinolone MIC distributions in the genetic context of examined\n            <jats:italic>Salmonella<\/jats:italic>\n            isolates clearly demonstrate that the prudent use of a lower susceptibility breakpoint minimizes the probability of clinical failure or delayed response in fluoroquinolone-treated patients.\n          <\/jats:p>","DOI":"10.1128\/aac.49.5.1775-1781.2005","type":"journal-article","created":{"date-parts":[[2005,4,26]],"date-time":"2005-04-26T23:32:47Z","timestamp":1114558367000},"page":"1775-1781","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":49,"title":["Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for\n            <i>Salmonella enterica<\/i>\n            Serotype Typhi"],"prefix":"10.1128","volume":"49","author":[{"given":"Brent M.","family":"Booker","sequence":"first","affiliation":[{"name":"The University at Buffalo School of Pharmacy and Pharmaceutical Sciences Applied Pharmacodynamics Laboratory"},{"name":"Roswell Park Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick F.","family":"Smith","sequence":"additional","affiliation":[{"name":"The University at Buffalo School of Pharmacy and Pharmaceutical Sciences Applied Pharmacodynamics Laboratory"},{"name":"Roswell Park Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Forrest","sequence":"additional","affiliation":[{"name":"The University at Buffalo School of Pharmacy and Pharmaceutical Sciences Applied Pharmacodynamics Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Bullock","sequence":"additional","affiliation":[{"name":"The University at Buffalo School of Pharmacy and Pharmaceutical Sciences Applied Pharmacodynamics Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Kelchlin","sequence":"additional","affiliation":[{"name":"The University at Buffalo School of Pharmacy and Pharmaceutical Sciences Applied Pharmacodynamics Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"The University at Buffalo School of Pharmacy and Pharmaceutical Sciences Applied Pharmacodynamics Laboratory"},{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"The JONES Group\/JMI Laboratories, North Liberty, Iowa"},{"name":"Tuft's University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"The University at Buffalo School of Pharmacy and Pharmaceutical Sciences Applied Pharmacodynamics Laboratory"},{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.827-829.2003"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.20.2668"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(03)00061-8","volume":"17","year":"2003","unstructured":"Ambrose, P. G., S. M. Bhavnani, and R. C. Owens, Jr. 2003. Clinical pharmacodynamics of quinolones. Infect. Dis. Clin. North Am.17:529-543.","journal-title":"Infect. Dis. Clin. North Am."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2793-2797.2001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1665-1670.2002"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/514624"},{"key":"e_1_3_2_8_2","unstructured":"Bristol-Myers Squibb Company. 2003. Gatifloxacin prescribing information. Bristol-Myers Squibb Wallingford Conn."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3201\/eid0704.017436","volume":"7","year":"2001","unstructured":"Chandel, D. S., and R. Chaudhry. 2001. Enteric fever treatment failures: a global concern. Emerg. Infect. Dis.7:762-763.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/375602"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/j.1469-0691.1998.tb00330.x","volume":"4","year":"1998","unstructured":"Drusano, G., M. T. Labro, O. Cars, P. Mendes, P. Shah, F. Sorgel, and W. Weber. 1998. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin. Microbiol. Infect.4(Suppl. 2):S27-S41.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.13-22.2001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(00)00132-6"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.7.1468"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.suppl_1.45"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.10.1925"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.10.2193"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.1592\/phco.20.8.67S.35185","volume":"20","year":"2000","unstructured":"LaCreta, F. P., G. D. Kollia, G. Duncan, D. Behr, and D. M. Grasela. 2000. Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy20:67S-75S.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1469-0691.1997.tb00304.x","volume":"3","year":"1997","unstructured":"Launay, O., J. C. Nguyen Van, A. Buu-Hoi, and J. F. Acar. 1997. Typhoid fever due to a Salmonella typhi strain of reduced susceptibility to fluoroquinolones. Clin. Microbiol. Infect.3:541-544.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1469-0691.1997.tb00313.x","volume":"3","year":"1997","unstructured":"Le Lostec, Z., S. Fegueux, P. Jouve, M. Cheron, P. Mornet, and A. Boisivon. 1997. Reduced susceptibility to quinolones in Salmonella typhi acquired in Europe: a clinical failure of treatment. Clin. Microbiol. Infect.3:576-577.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.4.703"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2293"},{"key":"e_1_3_2_25_2","unstructured":"National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing document M7-A6. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_26_2","unstructured":"National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing document M100-S14. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1469-0691.2000.00060-3.x","volume":"6","year":"2000","unstructured":"Nguyen, J. C., and F. W. Goldstein. 2000. Low-level resistance to fluoroquinolones among Salmonella and Shigella. Clin. Microbiol. Infect.6:231.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_28_2","unstructured":"Ortho-McNeil Pharmaceutical. 2003. Levofloxacin prescribing information. Ortho-McNeil Pharmaceutical Inc. Raritan N.J."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.125"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80103-X"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0924-8579(03)00063-3","volume":"22","year":"2003","unstructured":"Stephen, J. M., M. A. Toleman, T. R. Walsh, and R. N. Jones. 2003. Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). Int. J. Antimicrob. Agents22:395-405.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0703.017315"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01001-6"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/516128"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.5.1775-1781.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.5.1775-1781.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:50:01Z","timestamp":1645469401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.5.1775-1781.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1128\/AAC.49.5.1775-1781.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.5.1775-1781.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"2004-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}